Ocera Therapeutics Stock Price, News & Analysis (NASDAQ:OCRX)

$1.79 0.00 (0.00 %)
(As of 02/25/2018 12:07 PM ET)
Previous Close$1.79
Today's RangeN/A
52-Week Range$0.52 - $2.95
VolumeN/A
Average Volume913,190 shs
Market Capitalization$47.46 million
P/E Ratio-1.85
Dividend YieldN/A
Beta2.46

About Ocera Therapeutics (NASDAQ:OCRX)

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Receive OCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:OCRX
CUSIPN/A
Phone+1-650-4750158

Debt

Debt-to-Equity RatioN/A
Current Ratio1.27%
Quick Ratio1.27%

Price-To-Earnings

Trailing P/E Ratio-1.84536082474227
Forward P/E Ratio-1.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$610,000.00
Price / Sales77.79
Cash FlowN/A
Price / CashN/A
Book Value$0.68 per share
Price / Book2.63

Profitability

Trailing EPS($0.97)
Net Income$-26,890,000.00
Net MarginsN/A
Return on Equity-383.51%
Return on Assets-134.92%

Miscellaneous

Employees19
Outstanding Shares26,510,000

Ocera Therapeutics (NASDAQ:OCRX) Frequently Asked Questions

What is Ocera Therapeutics' stock symbol?

Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."

How were Ocera Therapeutics' earnings last quarter?

Ocera Therapeutics Inc (NASDAQ:OCRX) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.24). View Ocera Therapeutics' Earnings History.

Where is Ocera Therapeutics' stock going? Where will Ocera Therapeutics' stock price be in 2018?

3 brokerages have issued twelve-month price objectives for Ocera Therapeutics' stock. Their forecasts range from $1.75 to $11.00. On average, they expect Ocera Therapeutics' stock price to reach $5.25 in the next twelve months. View Analyst Ratings for Ocera Therapeutics.

Who are some of Ocera Therapeutics' key competitors?

Who are Ocera Therapeutics' key executives?

Ocera Therapeutics' management team includes the folowing people:

  • Linda S. Grais M.D., President, Chief Executive Officer, Director (Age 61)
  • Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 38)
  • Stan Bukofzer M.D., Chief Medical Officer (Age 59)
  • Steven P. James, Lead Independent Director (Age 57)
  • Willard H. Dere M.D., Director (Age 63)
  • Nina S. Kjellson, Independent Director (Age 40)
  • Anne M. VanLent, Independent Director (Age 68)
  • Eckard Weber M.D., Independent Director (Age 66)

How do I buy Ocera Therapeutics stock?

Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocera Therapeutics' stock price today?

One share of Ocera Therapeutics stock can currently be purchased for approximately $1.79.

How big of a company is Ocera Therapeutics?

Ocera Therapeutics has a market capitalization of $47.46 million and generates $610,000.00 in revenue each year. The biopharmaceutical company earns $-26,890,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Ocera Therapeutics employs 19 workers across the globe.

How can I contact Ocera Therapeutics?

Ocera Therapeutics' mailing address is 555 Twin Dolphin Dr Ste 615, REDWOOD CITY, CA 94065-2130, United States. The biopharmaceutical company can be reached via phone at +1-650-4750158 or via email at [email protected]


MarketBeat Community Rating for Ocera Therapeutics (OCRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ocera Therapeutics (NASDAQ:OCRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldBuy
Consensus Rating Score: 2.672.402.252.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.25$4.19$1.92$4.50
Price Target Upside: 193.30% upside133.94% upside68.13% upside294.74% upside

Ocera Therapeutics (NASDAQ:OCRX) Consensus Price Target History

Price Target History for Ocera Therapeutics (NASDAQ:OCRX)

Ocera Therapeutics (NASDAQ:OCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017CowenReiterated RatingBuy$11.00LowView Rating Details
11/3/2017HC WainwrightDowngradeBuy -> Neutral$1.75N/AView Rating Details
5/24/2017AegisReiterated RatingBuy$3.00LowView Rating Details
1/31/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
1/30/2017Stifel NicolausDowngradeBuy -> Hold$1.00N/AView Rating Details
10/24/2016Brean CapitalSet Price TargetBuy$10.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Ocera Therapeutics (NASDAQ:OCRX) Earnings History and Estimates Chart

Earnings by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Ocera Therapeutics (NASDAQ OCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.24)($0.24)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.24)($0.23)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.24)($0.28)ViewListenView Earnings Details
3/10/2017Q4 2016($0.34)($0.22)$0.01 million$0.51 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.36)($0.32)$0.04 millionViewN/AView Earnings Details
8/3/2016Q2 2016($0.33)$0.03 millionViewN/AView Earnings Details
4/29/2016Q1($0.33)($0.36)$0.03 millionViewN/AView Earnings Details
3/3/2016Q415($0.33)($0.34)$0.02 millionViewN/AView Earnings Details
11/4/2015Q3 2015($0.39)($0.34)$0.04 millionViewN/AView Earnings Details
8/3/2015Q215($0.40)($0.46)$0.04 millionViewN/AView Earnings Details
4/30/2015Q115($0.29)($0.34)$0.03 millionViewN/AView Earnings Details
3/11/2015Q414($0.46)($0.28)$0.03 millionViewN/AView Earnings Details
11/13/2014Q314($0.50)($0.34)$0.23 millionViewN/AView Earnings Details
8/11/2014Q114($0.45)($0.46)$0.03 millionViewN/AView Earnings Details
5/8/2014($0.43)($0.27)$0.05 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.48)$2.93 million$52.00 millionViewN/AView Earnings Details
11/13/2013Q3 13($0.77)$0.20 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.24)($1.07)$0.13 million$0.89 millionViewN/AView Earnings Details
5/9/2013Q1 2013($1.20)($1.44)$1.81 million$0.60 millionViewN/AView Earnings Details
3/28/2013Q4 2012($0.30)($0.18)$1.70 million$1.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.29)($0.16)$1.99 million$1.80 millionViewN/AView Earnings Details
8/9/2012Q2 2012($2.76)($2.74)ViewN/AView Earnings Details
5/10/2012Q1 2012($4.08)($4.11)ViewN/AView Earnings Details
2/28/2012Q4 2011($3.60)($3.96)ViewN/AView Earnings Details
11/10/2011Q3 2011($3.36)($3.13)ViewN/AView Earnings Details
8/11/2011Q2 2011($2.28)($2.28)ViewN/AView Earnings Details
5/12/2011Q1 2011($3.96)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ocera Therapeutics (NASDAQ:OCRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:OCRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ocera Therapeutics (NASDAQ OCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 17.69%
Insider Trades by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Institutional Ownership by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Ocera Therapeutics (NASDAQ OCRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2017Michael ByrnesCFOBuy3,000$1.28$3,840.0013,000View SEC Filing  
12/7/2016Linda S GraisInsiderBuy7,000$2.14$14,980.0070,000View SEC Filing  
10/13/2016Stan BukofzerInsiderBuy2,500$2.64$6,600.002,500View SEC Filing  
3/4/2016Linda S GraisCEOBuy3,000$3.19$9,570.0063,000View SEC Filing  
1/22/2016Linda S GraisCEOBuy10,000$2.38$23,800.0060,000View SEC Filing  
1/15/2016Gaurav AggarwalInsiderBuy10,000$2.15$21,500.0020,000View SEC Filing  
1/15/2016Michael ByrnesCFOBuy3,500$2.07$7,245.0010,000View SEC Filing  
6/23/2015Wendall WierengaDirectorBuy5,000$3.71$18,550.00View SEC Filing  
5/7/2015Rajiv PatniInsiderBuy5,050$3.97$20,048.50View SEC Filing  
5/6/2015Gaurav AggarwalInsiderBuy7,500$3.62$27,150.00View SEC Filing  
5/6/2015Linda S GraisCEOBuy30,000$3.73$111,900.00View SEC Filing  
5/6/2015Michael ByrnesCFOBuy2,500$3.61$9,025.00View SEC Filing  
10/1/2014Michael ByrnesVPBuy2,000$4.81$9,620.00View SEC Filing  
7/11/2014Linda S GraisCEOBuy10,000$5.93$59,300.00View SEC Filing  
7/11/2014Sharon TetlowCFOBuy3,000$5.83$17,490.00View SEC Filing  
7/15/2013Brian K HalakMajor ShareholderBuy995,618$6.03$6,003,576.54View SEC Filing  
7/15/2013Michael PowellDirectorBuy391,166$6.03$2,358,730.98View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ocera Therapeutics (NASDAQ OCRX) News Headlines

Source:
DateHeadline
Sinovac Biotech (SVA) & Ocera Therapeutics (OCRX) Financial SurveySinovac Biotech (SVA) & Ocera Therapeutics (OCRX) Financial Survey
www.americanbankingnews.com - February 6 at 9:14 AM
Contrasting Ocera Therapeutics (OCRX) and 3SBio (SSRX)Contrasting Ocera Therapeutics (OCRX) and 3SBio (SSRX)
www.americanbankingnews.com - February 2 at 3:38 PM
Ocera Therapeutics (OCRX) & Synlogic (SYBX) Financial ContrastOcera Therapeutics (OCRX) & Synlogic (SYBX) Financial Contrast
www.americanbankingnews.com - January 27 at 5:20 AM
Analyzing Auxilium Pharmaceuticals (AUXL) & Ocera Therapeutics (OCRX)Analyzing Auxilium Pharmaceuticals (AUXL) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - January 22 at 5:20 AM
Ocera Therapeutics Inc (OCRX) Receives Consensus Recommendation of "Hold" from BrokeragesOcera Therapeutics Inc (OCRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 12 at 8:36 PM
Ocera Therapeutics Inc (OCRX) Given Consensus Recommendation of "Hold" by AnalystsOcera Therapeutics Inc (OCRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 18 at 10:16 PM
Ocera Therapeutics (OCRX) Given "Buy" Rating at CowenOcera Therapeutics (OCRX) Given "Buy" Rating at Cowen
www.americanbankingnews.com - December 18 at 8:26 PM
Want To Invest In Ocera Therapeutics Inc (undefined:OCRX)? Here’s How It Performed LatelyWant To Invest In Ocera Therapeutics Inc (undefined:OCRX)? Here’s How It Performed Lately
finance.yahoo.com - December 13 at 8:29 AM
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Ocera Therapeutics, Inc.SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Ocera Therapeutics, Inc.
feeds.benzinga.com - December 7 at 9:47 PM
 Brokerages Expect Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.20 Per Share Brokerages Expect Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - December 6 at 7:52 AM
 Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) to Announce -$0.20 Earnings Per Share Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - November 18 at 1:30 PM
At $1.75, Is It Time To Buy Ocera Therapeutics Inc (OCRX)?At $1.75, Is It Time To Buy Ocera Therapeutics Inc (OCRX)?
finance.yahoo.com - November 18 at 10:08 AM
Ocera Therapeutics, Inc. (OCRX) Stock Rating Lowered by HC WainwrightOcera Therapeutics, Inc. (OCRX) Stock Rating Lowered by HC Wainwright
www.americanbankingnews.com - November 5 at 6:20 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ocera Therapeutics, Inc. to Mallinckrodt plc is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ocera Therapeutics, Inc. to Mallinckrodt plc is Fair to Shareholders
finance.yahoo.com - November 4 at 4:07 PM
OCERA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BuyoutOCERA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - November 4 at 4:07 PM
Mid-Afternoon Market Update: Ocera Therapeutics Surges Following ... - NasdaqMid-Afternoon Market Update: Ocera Therapeutics Surges Following ... - Nasdaq
www.nasdaq.com - November 4 at 8:23 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRX - PR Newswire (press release)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRX - PR Newswire (press release)
www.prnewswire.com - November 4 at 8:23 AM
Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic EncephalopathyMallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
finance.yahoo.com - November 2 at 7:13 AM
Mallinckrodt will buy biotech Ocera Therapeutics for about $42 mlnMallinckrodt will buy biotech Ocera Therapeutics for about $42 mln
finance.yahoo.com - November 2 at 7:13 AM
Ocera Therapeutics, Inc. (OCRX) Sees Large Decline in Short InterestOcera Therapeutics, Inc. (OCRX) Sees Large Decline in Short Interest
www.americanbankingnews.com - October 28 at 2:26 AM
Contrasting KalVista Pharmaceuticals (KALV) and Ocera Therapeutics (OCRX)Contrasting KalVista Pharmaceuticals (KALV) and Ocera Therapeutics (OCRX)
www.americanbankingnews.com - October 27 at 7:24 PM
Ocera Therapeutics (OCRX) to Present Three Posters, Oral Presentation on OCR-002 at AASLD - StreetInsider.comOcera Therapeutics (OCRX) to Present Three Posters, Oral Presentation on OCR-002 at AASLD - StreetInsider.com
www.streetinsider.com - October 21 at 7:18 AM
Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
finance.yahoo.com - October 21 at 7:18 AM
Ocera Therapeutics, Inc. (OCRX) Given Average Rating of "Buy" by BrokeragesOcera Therapeutics, Inc. (OCRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 1:24 PM
Critical Review: Chiasma (CHMA) & Ocera Therapeutics (OCRX)Critical Review: Chiasma (CHMA) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - October 6 at 2:08 AM
Will Ocera Therapeutics Inc (OCRX) Need To Raise More Money?Will Ocera Therapeutics Inc (OCRX) Need To Raise More Money?
finance.yahoo.com - October 5 at 6:37 PM
Ocera Therapeutics, Inc. (OCRX) Receives Average Rating of "Buy" from BrokeragesOcera Therapeutics, Inc. (OCRX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 24 at 10:36 AM
Ocera Therapeutics, Inc. (OCRX) Expected to Announce Earnings of -$0.23 Per ShareOcera Therapeutics, Inc. (OCRX) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 21 at 6:24 AM
Reviewing Baxalta (BXLT) & Ocera Therapeutics (OCRX)Reviewing Baxalta (BXLT) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - September 20 at 12:16 AM
Financial Contrast: Catalyst Biosciences (CBIO) vs. Ocera Therapeutics (OCRX)Financial Contrast: Catalyst Biosciences (CBIO) vs. Ocera Therapeutics (OCRX)
www.americanbankingnews.com - September 16 at 6:30 PM
Head-To-Head Survey: Ocera Therapeutics (OCRX) & Its PeersHead-To-Head Survey: Ocera Therapeutics (OCRX) & Its Peers
www.americanbankingnews.com - September 13 at 6:20 AM
 Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.23 Per Share Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 2 at 12:10 PM
Ocera Therapeutics, Inc. (OCRX) Given Average Recommendation of "Buy" by BrokeragesOcera Therapeutics, Inc. (OCRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 10:56 AM
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver ... - NasdaqOcera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver ... - Nasdaq
www.nasdaq.com - August 23 at 9:38 AM
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017
finance.yahoo.com - August 23 at 9:38 AM
Transition Therapeutics (TTHI) versus Ocera Therapeutics (OCRX) Financial ContrastTransition Therapeutics (TTHI) versus Ocera Therapeutics (OCRX) Financial Contrast
www.americanbankingnews.com - August 19 at 2:26 AM
Ocera Therapeutics: When A Drug Fails, But Actually Works - Seeking AlphaOcera Therapeutics: When A Drug Fails, But Actually Works - Seeking Alpha
seekingalpha.com - August 10 at 6:26 AM
Ocera Therapeutics Inc (NASDAQ:OCRX) Receives Average Recommendation of "Buy" from BrokeragesOcera Therapeutics Inc (NASDAQ:OCRX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 10:24 AM
Ocera Therapeutics, Inc. (NASDAQ:OCRX) Issues Quarterly  Earnings Results, Beats Estimates By $0.01 EPSOcera Therapeutics, Inc. (NASDAQ:OCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 2 at 6:00 PM
Ocera Therapeutics Reports Second Quarter 2017 Financial ResultsOcera Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:32 AM
Financial Survey: Ocera Therapeutics (NASDAQ:OCRX) versus Strongbridge Biopharma PLC (SBBP)Financial Survey: Ocera Therapeutics (NASDAQ:OCRX) versus Strongbridge Biopharma PLC (SBBP)
www.americanbankingnews.com - July 27 at 8:11 PM
Ocera Therapeutics, Inc. (OCRX) Receives Consensus Rating of "Hold" from BrokeragesOcera Therapeutics, Inc. (OCRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 11 at 10:32 AM
Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis - StreetInsider.comOcera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis - StreetInsider.com
www.streetinsider.com - June 2 at 9:02 PM
Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with CirrhosisOcera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis
www.streetinsider.com - June 1 at 7:48 PM
Ocera Therapeutics to Host KOL Conference Call on Hepatic ... - NasdaqOcera Therapeutics to Host KOL Conference Call on Hepatic ... - Nasdaq
www.nasdaq.com - May 26 at 7:58 PM
Ocera Therapeutics (OCRX) CEO Linda Grais on Q1 2017 Results - Earnings Call Transcript - Seeking AlphaOcera Therapeutics' (OCRX) CEO Linda Grais on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 13 at 8:17 AM
Ocera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers GuidanceOcera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers Guidance
www.streetinsider.com - May 12 at 12:30 AM
BUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, HanesBrands ... - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, HanesBrands ... - Nasdaq
www.nasdaq.com - April 13 at 11:47 PM
After-Hours Stock Movers 04/12: (OCRX) (AAOI) (HBI) Higher; (SRNE) (DMPI) (PIR) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 04/12: (OCRX) (AAOI) (HBI) Higher; (SRNE) (DMPI) (PIR) Lower (more...) - StreetInsider.com
www.streetinsider.com - April 13 at 8:04 AM
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhiOCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - March 31 at 7:05 PM

SEC Filings

Ocera Therapeutics (NASDAQ:OCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ocera Therapeutics (NASDAQ:OCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ocera Therapeutics (NASDAQ OCRX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.